Dengvaxia’s Restrictive Indication Will Make Immunization Recommendations Difficult, ACIP Members Say

The need to screen individuals in dengue-endemic areas for prior infection before administering Sanofi’s vaccine will be difficult to operationalize, particularly in the absence of a reliable and rapid diagnostic, experts say; Advisory Committee on Immunization Practices working group aims for full committee vote on use recommendations in February 2020.

Mosquito bites hand concept, Mosquito sucking blood on skin of hand on blurred green forest background For children being bitten by mosquitoes is a scary thing. Dengue fever or related illness. - Image
ACIP has a difficult task ahead of it in making immunization recommendations targeting the mosquito-borne dengue virus. • Source: Shutterstock

The challenges of developing and implementing an immunization recommendation for Sanofi’s dengue vaccine Dengvaxia were readily apparent at the recent meeting of the US Advisory Committee for Immunization Practices.

Even though the Centers for Disease Control and Prevention panel is not expected to vote on a use recommendation until...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Vaccines

More from Pink Sheet

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By 

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.

UK Looks To Auto-Match NHS Patients With Clinical Trials To Boost Recruitment

 
• By 

The UK government is making it easier for millions of people to participate in clinical trials and is boosting transparency around how studies are delivered across the National Health Service.

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.